Technology/ Title
|
Development of CSF-1R antibody drug to target tumor associated macrophage for cancer immunotherapy
|
Technology Type
|
□Biotechnology
|
□Device/Diagnostics
|
■Pharmaceutical
|
□Others:_____________-
|
Contact Person
|
Name: Kuan-Tsung Lin
|
Title: Project Manager
|
Telephone(work): +886-02-7700-3800 ext. 5239
|
Email:
ktlin2@dcb.org.tw
|
2019 BioAsia
Information
Download
|
https://www.dcb.org.tw/posts/729
|
Technology Description
|
- CSF-1R (colony-stimulating factor-1 receptor) is a cell surface receptor for the macrophage colony stimulating factor (M-CSF or CSF-1) and IL-34. It is required for the proliferation and survival and differentiation of cells of monocyte/macrophage lineage. Elevated expression or activation of CSF-1R and/or its ligand has been found in a variety of cancers, and elevated levels of M-CSF are associated with poor prognosis in certain cancers. M-CSF is one of several cytokines implicated in the recruitment of tumor-associated macrophages (TAMs), which exhibit similar characteristics to M2 macrophages and contribute to tumor angiogenesis and tumor progression to metastasis. Targeting TAM through CSF-1R signaling by neutralizing antibody is therefore an attractive strategy to treat oncological and inflammatory/immunological diseases.
- This CSF-1R lead antibody shows high affinity, neutralizing ability, novel CDRs sequence and non-overlapping epitopes with other CSF-1R antibodies. US provisional patent was filed.
- Advantages when compared to the existing technologies:
- In vitro & in vivo platforms for CSF-1R antibody screening.
- Characterization and analytical platforms for CSF-1R antibody.
- Novel CDRs and novel epitopes for DCB’s CSF-1R antibody.
- Potential to combine with PD-1/PD-L1 antibody.
|
Intellectual Property
|
US provisional patent applied
|
Business Opportunity
|
Immune-oncology cancer therapy
|